Alliance for Clinical Trials in Oncology
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2011-01-01
- Employees
- 251
- Market Cap
- -
Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma
- Conditions
- Interventions
- First Posted Date
- 2023-01-23
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 77
- Registration Number
- NCT05694871
- Locations
- 🇺🇸
UH Seidman Cancer Center at UH Avon Health Center, Avon, Ohio, United States
🇺🇸Creighton University Medical Center, Omaha, Nebraska, United States
🇺🇸Fresno Cancer Center, Fresno, California, United States
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
- Conditions
- Clinical Stage III Gastric Cancer AJCC v8Advanced Esophageal AdenocarcinomaClinical Stage III Esophageal Adenocarcinoma AJCC v8Unresectable Esophageal AdenocarcinomaUnresectable Gastroesophageal Junction AdenocarcinomaAdvanced Gastric AdenocarcinomaAdvanced Gastroesophageal Junction AdenocarcinomaClinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Esophageal Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8
- Interventions
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 382
- Registration Number
- NCT05677490
- Locations
- 🇺🇸
CARTI Cancer Center, Little Rock, Arkansas, United States
🇺🇸Sutter Auburn Faith Hospital, Auburn, California, United States
🇺🇸Sutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California, United States
Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Registration Number
- NCT05677373
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study
- Conditions
- Interventions
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 364
- Registration Number
- NCT05673148
- Locations
- 🇺🇸
Helen F Graham Cancer Center, Newark, Delaware, United States
🇺🇸Medical Oncology Hematology Consultants PA, Newark, Delaware, United States
🇺🇸Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States
Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma
- First Posted Date
- 2022-12-12
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 26
- Registration Number
- NCT05647265
- Locations
- 🇺🇸
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States
🇺🇸Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation
- Conditions
- Interventions
- First Posted Date
- 2022-11-09
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 312
- Registration Number
- NCT05610163
- Locations
- 🇺🇸
Lutheran Hospital - Cancer Centers of Colorado, Golden, Colorado, United States
🇺🇸Intermountain Health Lutheran Hospital, Wheat Ridge, Colorado, United States
🇺🇸Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida, United States
Testing Laser Therapy for Treatment of Vaginal Dryness in Survivors of Breast Cancer, The Revitalize Trial
- Conditions
- Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Vaginal AtrophyAnatomic Stage 0 Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8
- Interventions
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 250
- Registration Number
- NCT05379153
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Conditions
- Ann Arbor Stage I LymphomaChronic Lymphocytic LeukemiaGastroesophageal Junction AdenocarcinomaHead and Neck CarcinomaMalignant Hepatobiliary NeoplasmMelanomaStage I Pancreatic Cancer AJCC v6 and v7Stage I Prostate Cancer AJCC v7Stage II Breast Cancer AJCC v6 and v7Stage II Pancreatic Cancer AJCC v6 and v7
- Interventions
- First Posted Date
- 2022-04-19
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 2000
- Registration Number
- NCT05334069
- Locations
- 🇺🇸
Mercy Cancer Center - Elk Grove, Elk Grove, California, United States
🇺🇸Bay Area Breast Surgeons Inc, Emeryville, California, United States
🇺🇸Epic Care Partners in Cancer Care, Emeryville, California, United States
Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 66
- Registration Number
- NCT05303792
- Locations
- 🇺🇸
NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States
🇺🇸Marshfield Medical Center - Weston, Weston, Wisconsin, United States
🇺🇸Marshfield Medical Center-River Region at Stevens Point, Stevens Point, Wisconsin, United States
Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 198
- Registration Number
- NCT05247905
- Locations
- 🇺🇸
Advocate Outpatient Center - Aurora, Aurora, Illinois, United States
🇺🇸Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States
🇺🇸MU Health Care Goldschmidt Cancer Center, Jefferson City, Missouri, United States